Outpatient treatment of deep vein thrombosis (DVT) has become a common practice in uncomplicated patients. Few data are still present in patients with comorbidity (such as cancer) or concomitant symptomatic pulmonary embolism. Cancer patients with DVT are often excluded from home treatment because they have a higher risk of both bleeding and recurrent DVT. We tested the feasibility and safety of the Home Treatment (HT) program for acute DVT a PE in cancer patients. Patients were treated as outpatients unless they required admission for other medical problems, were actively bleeding or had pain that requires parenteral narcotics. Outpatient treatment was with low molecular weight heparin (LMWH) followed by warfarin or with LMWH alone. An educational program for patients was implemented. Two-hundred and seven patients with cancer were evaluated, 36 (17.4%) of whom had metastatic disease. Treatment with LMWH and warfarin was prescribed to 106 (51.2%) and LMWH alone to 102 (48.8%). One hundred and twenty-seven patients (61.3%) were entirely treated at home. There were no differences between patients treated at home and hospitalized patients with regard to gender, mean age, site of cancer, presence of metastases, and treatment. After 6 months, recurrent thrombo-embolism occurred in 8.7% of patients treated at home and in 5.6% of hospitalized patients (P = 0.58); major bleeding in 2.0% and 1.5%, respectively (P = 0.06). Twenty-seven patients (33%) in the hospitalized, and 33 (26%) in the home-treatment group, died after a follow-up of 6 months. These results indicate that, regarding cancer patients with acute DVT and/or PE, there is no difference between hospitalised and home-treated patients in terms of major outcomes.
Introduction
The association between cancer and venous thrombosis is well established [1] . The prevalence of known cancer ranges from 10 to 20% at the time of VTE is diagnosed and at least 8-10% of cancer patients will developed a venous thrombotic event during their illness [2] . Treatment of VTE in cancer patients is problematic because of the increased risk of recurrent thrombosis (despite well conducted anticoagulant therapy) and because of major bleeding during anticoagulation due to concomitant anti-cancer therapy and medical co-morbidities [3] . For these reasons, in case of a thrombotic event cancer patients are considered at high-risk for complications. Because of the introduction of LMWH, home treatment of deep vein thrombosis (DVT) is a common practice in Europe and North America [4, 5] . However, no clear consensus is present and the range of physicians who actually treated patients at home widely varies from 18% to up than 80% [6] . The situation is even less clear in cancer patients, since they have concomitant medical problems that complicate initial anticoagulation care, thus suggesting hospitalization for VTE treatment [7, 8] . On the other hand, these patients may be inclined towards hometreatment because of a potential positive impact on their quality of life. Recent trials have shown that LMWHs can successfully replace warfarin therapy for the long treatment of cancer patients affected by acute VTE thus simplifying the management of these complicated patients [9, 10] . However, few data are present about the safety and efficacy of such approach on home basis [9, 10] . Critically, no data are present in patients affected by symptomatic stable Pulmonary Embolism (PE) who can be treated at home [11] . In this study we assessed the feasibility of home treatment of acute DVT and PE in cancer patients and compared the outcomes in the hospitalized and home-treated patients. 
Materials and methods
Outpatients presenting with acute VTE (DVT and/or PE) and active cancer (ongoing or palliative) at the Thrombosis and Haemostasis Unit of the University Hospital of Palermo during a period of 3 years (2001) (2002) (2003) (2004) were considered eligible for the study. All patients with objectively confirmed VTE were included and evaluated for the home treatment program. We applied the following criteria for hospital admission: (i) poor clinical conditions related to concomitant medical disorders, (ii) illness that independently required hospitalisation, (iii) poor compliance, (iv) high risk of bleeding or active bleeding, (v) renal insufficiency, (vi) acute anemia, (vii) pain requiring parenteral narcotics. Patients' age, gender, site of DVT, concomitant, objectively confirmed symptomatic pulmonary embolism, time between diagnosis of cancer and diagnosis of DVT, site of cancer, presence of metastases and the specifics of cancer treatment were recorded. For hospitalized patients, the reason for admission and the mean duration of stay were documented. The diagnostic protocols for acute and recurrent DVT and PE were performed accordingly to the commonly accepted procedures [12, 13] .
Diagnosis of DVT
Patients were considered to have DVT when a fully non compressibility of the veins of the symptomatic lower limb (in the proximal or distal segments) was detected by Compression UltraSonography (CUS positive). In case of negative CUS results but positive D-dimer, a serial CUS was planned after 1 week and managed accordingly [12] .
Diagnosis of PE
Patients with the clinical suspicion of PE (considered as the predominant signs and symptoms) underwent bilateral CUS of the lower limbs and ventilation/perfusion lung scanning (V/Q) or Computed Tomography (CT) of the lung. In case of positive CUS, patients were considered to have PE and no further test were planned; when all diagnostic tests along with D-dimer assay were negative, the diagnosis of PE was ruled out [13] . In case of indeterminate V/Q or CT lung scan patients were managed accordingly to their Pre-test Clinical Probability (PCP) and/or D-dimer test results at presentation; pulmonary angiography was taken in account in patients without poor clinical condition. The Dimertest w (Dade Behring, Deerfield Ill) was performed as previously described [14] .
Diagnosis of recurrent VTE
Recurrent DVT was defined as the detection of a new thrombus or the extension of the previous thrombus detected by CUS; in all other cases, venography was required. In PE patients, new defect in V/Q or CT lung scan, worsening of signs and symptoms along with deterioration of chest X-ray or blood gas or EKG or leg swelling with a positive CUS was considered.
Bleeding
Bleeding was defined as major if it was overt and associated with either a decrease in haemoglobin levels of at least 2.0 g/dL or a need for transfusion of two or more units of blood. Bleeding was defined as minor if it was overt but did not meet the other criteria for major bleeding [15] .
All patients, either hospitalised or out-patients, were treated with subcutaneous, weight-adjusted, once or twice-daily low molecular weight heparins. Then patients initiated warfarin therapy or continued LMWH at two-thirds of the entire dosage [8] . Antithrombotic therapy was continued for at least 6 months. Educational session
All patients were educated about the self administration of subcutaneous LMWH and about the monitoring of oral anticoagulation. They were also informed about the progression of signs for PE and DVT or the occurrence of bleeding.
Follow-up evaluation
All events (rVTE, major and minor bleeding), occurred during the study period were monitored in hospitalised patients and out-patients.
Statistics and ethics
The rate of any event that occurred was determined and 95% Confidence Intervals (CI) were calculated. Paired t and Pearson x 2 tests were applied where indicated; a P value of <5% (two-tailed) was considered statistically significant. The mean age of hospitalised and outpatients was compared by a t-test; gender, the rate of recurrent events and bleeding were compared a x 2 test All patients were informed about the study design and gave their consent to the study.
Results
Two-hundred and seven consecutive patients with cancer and VTE were evaluated during the period September 2001-September 2004. Among these, 139 had DVT and 68 had PE (Table 1) . One-hundred and twenty-seven patients were entirely treated at home (61.3%) whereas 80 required hospitalisation. Inpatients were slightly, but not significantly older than outpatients. There were not differences in gender between the two groups. Concomitant medical problem were equally distributed among hospitalised and home-treated patients. The mean time between diagnosis of cancer and VTE was 28.1 months, the most common site of cancer was the gastrointestinal tract; 38% of patients had known metastases at the time of VTE diagnosis. Cancer treatment was ongoing in 42.5% of patients, most of whom were receiving chemotherapy. For patients who required hospitalization (38.6%), the mean hospital stay was 9.1 days; reasons for hospitalisation are listed in Table 2 . Treatment with LMWH and warfarin was administered to 106 patients (51.2%), LMWH alone was administered to the remaining 101 patients (48.8%). No differences were found in the number of patients with distal DVT, upper limb DVT or with bilateral lower limb DVT treated at home or hospitalised ( Table 1 ). The tumor type/origin and the proportion of patients with metastatic disease were similar between patients treated at home and patients treated in hospital. Finally, there was no difference in antithrombotic treatment between the two groups. After 6 months of follow-up, sixty patients (29%) died. Considering all patients (outpatients and hospitalized), recurrent VTE and major bleeding occurred in 15 (6.7%) and 3 of them (1.5%), respectively. Comparing outpatients and hospitalized patients, the rate of recurrent VTEs (8.7% versus 5.5% respectively; P = 0.58) and major bleeding events (1.2% versus 1.5% respectively; P = 0.76) was similar ( Table 3 ).
Discussion
Cancer is frequently considered a criterion for exclusion from home treatment of DVT and in many centers these patients are routinely admitted to hospital. We decided to conduct a prospective study for evaluating the safety of home therapy for VTE in cancer patients. To our knowledge, this is the first prospective study that has specifically addressed the initial outpatient management of DVT and PE in cancer patients.
Our study furnishes evidences for treating at home patients with cancer suffering of an episode of acute VTE. This approach is safe since the events occurred in home-treated patients during a follow-up of 6 months overlaps with that occurred in patients who received standard hospitalisation. However, our patients were not less risky than that hospitalised since the prevalence of extensive DVT, symptomatic PE and concomitant diseases was similar between the two groups. Our approach permitted to apply the HT program in more than 60% of the entire court of patients; this is even more important since our data refer to a population with a high rate of concomitant medical disorders. The predominant reason for providing treatment in hospital were the need of investigating relapse of cancer or the presence of concomitant medical problems usually related to complications of cancer. Our patients well represent a population of cancer patients with VTE.
Although our approach has not still been evaluated economically, it seems likely to be also cost-effective [16] . Almost half of our patients received long-term treatment with LMWH; this approach was similar between patients treated at home or those hospitalised. Recent trials highlight the advantage of using LMWH for the initial and long-term treatment for acute DVT; this seems true either for reducing the risk of recurrent DVT or for ameliorating patients' survival in nonmetastastic cancer [8] . Clearly, the absence of laboratory monitoring by using LMWH can further increase the home treatment of acute VTE also in this category of high-risk patients. This is even more important since most of cancer patients usually receive chemotherapy that heavy interferes with oral anticoagulants. Few studies have evaluated the possibility of treating at home patients with symptomatic PE and none, at our knowledge, PE patients with cancer. Our population of PE patients treated at home represented 28% of the entire cohort; in this category of patients the incidence of recurrent PE, major bleeding and death occurred after 6 months was similar to that reported in DVT patients.
In conclusion, we believe that cancer patients can derive important benefits for home treatment since a new hospitalisation usually deteriorate their quality of life. Physicians should keep in mind that even in this category of high-risk patients, the advantage of home treatment for acute VTE is substantial. What are the clinical implications of the present investigation? Our results suggest that, even in high-risk patients, a careful HT program performed in appropriate setting is as feasible and safe as standard in-hospital management or HT for uncomplicated DVT.
